Citations

Clear

3138 citation(s) found for "Smith, AM".

Impact of routine collection of electronic patient-reported outcome measures (ePROMs) coupled with a collaborative care (CC)-based symptom intervention in patients with early-onset colorectal cancer (eoCRC).
Jin, Zhaohui, Ruddy, Kathryn J. , Pachman, Deirdre R. , Kour, Oudom, Rahman, Parvez, Greenmyer, Jacob R. , Augustin, Ryan Christian, Grzegorczyk, Veronica , Smith, Ashley , Mitchell, S. Weir, Shi, Qian , Storandt, Michael H. , Jin, Zhaohui , Rahman, Parvez, Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 64-64

10.1200/jco.2026.44.2_suppl.64 Get It

64 Background: The incidence of eoCRC (diagnosed at age <50) is increasing. We have previously shown higher rates of severe anxiety and depression in this group compared to adults diagnosed at age ≥50 (average-onset CRC, aoCRC). We assessed the impact of ePROM collection coupled with a CC-based supportive care intervention on symptom burden in patients with eoCRC. Methods: The Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) trial was a cluster-randomized, pragmatic trial conducted at Mayo Clinic Rochester and within the Mayo Clinic Health System (in Minnesota and Wisconsin) between 2019 and 2023. Enrolled patients serially reported the severity of six SPPADE symptoms (Sleep deficit, Pain, Physical function impairment, Anxiety, Depression, and Energy deficit/fatigue) on 11-point numerical rating scales. Symptom scores were interpreted as none to mild (0-3), moderate (4-6), or severe (7-10). Those with moderate symptoms were offered symptom management education and self-management materials, while those with severe symptoms were offered the option to work with a symptom care manager. In this post hoc analysis we examined the effects of the intervention on change in symptom scores among those with eoCRC, and using the Kaplan-Meier method, the median time to improvement to a mild/moderate level in those with a severe symptom, comparing eoCRC with aoCRC. Results: Among 4,422 patients with CRC, 887 had eoCRC. Forty-six percent of patients were female ( p =0.61), and a greater proportion of eoCRC patients were of a non-white race (11.6% vs 4.7%), lived in an urban setting (65.6% vs 50.5%), had a Bachelor’s degree or higher (36.8% vs 24.4%), were employed (78.5% vs 36.7%), on a non-government insurance plan (83.4% vs 35.3%), single (19.7% vs 11.2%) or married (74.2% vs 67.9%), and had metastatic disease (54.8% vs 46.1%, p <0.0001 for all). Compared to a pre-intervention baseline, the mean change in symptom scores for eoCRC patients following the intervention demonstrated improvements in anxiety (-0.238), depression (-0.134), and fatigue (-0.146, p <0.05 for all). Time to symptom improvement from severe to mild/moderate was longer for anxiety and depression in eoCRC patients compared to aoCRC patients (Table 1). Conclusions: Collection of ePROMs coupled with a CC-based intervention led to improvements in anxiety, depression, and fatigue among eoCRC patients, although time to symptom improvement was longer among eoCRC patients compared to aoCRC patients. Time to improvement of severe symptom (months), median (95% CI). eoCRC aoCRC p -value Sleep 4.2 (3.1-5.8) 3.8 (2.7-5.4) 0.4 Pain 4.1 (3.0-7.5) 3.2 (2.3-5.0) 0.5 Physical function impairment 3.1 (1.9-6.3) 2.8 (2.2-4.2) 0.5 Anxiety 4.3 (3.4-9.1) 2.6 (2.0-3.5) 0.009 Depression 4.3 (2.6-7.5) 2.6 (2.1-3.5) 0.04 Fatigue 4.3 (3.7-9.5) 3.4 (2.7-4.2) 0.06
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826
Castellino, Sharon M., Li, H., Herrera, Alex F. , LeBlanc, Michael, Parsons, SK, Unger, Joseph M., Punnett, Angela , Hodgson, David, Keller, FG, Drachtman, Richard A. , Lamble, Adam J. , Doan, Andrew , Rutherford, Sarah C. , Little, Richard F. , Song, Joo Y., Smith, Sonali M. , Friedberg, Jonathan W. , Kelly, Kara M., Unger, Joseph M. , Castellino, Sharon M. , Parsons, Susan K. , Hodgson, David , Keller, Frank G. , Castellino, Sharon , Li, Hongli , K Parsons, Susan , Unger, Joseph M , Hodgson, David , Keller, Frank G , Lamble, Adam , Doan, Andrew , Rutherford, Sarah C , Evens, Andrew M , Little, Richard F , Smith, Malcolm A , Hoppe, Bradford S , Song, Joo Y , Kelly, Kara M , LeBlanc, Michael L., Forlenza, Christopher J. , Evens, Andrew M. , Smith, Malcolm A. , Hoppe, Bradford S. , Kelly, Kara M.

Mayo Clinic

Journal of Clinical Oncology | January 9, 2026 | Volume: 44 | Issue: 6 | Pages: 449-454

10.1200/jco-25-00203 | PMID 41512237 Get It

We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
Induction Regimens and Kidney Re‐Transplant Outcomes after BK Nephropathy–Related Graft Loss: A U.S. Cohort Study
El‐Rifai, Rasha , Fontana, Lauren, Jackson, Scott M. , Smith, Byron H. , Shams, Amir Hossein , Quintiliano, Artur, Bentall, Andrew , Razonable, Raymund R., Kandaswamy, Raja, Riad, Samy M. , Riad, Samy , Fontana, Lauren , Bentall, Andrew , Smith, Byron , Jackson, Scott, Razonable, Raymund R. , Kandaswamy, Raja

Mayo Clinic

Clinical Transplantation | January 9, 2026 | Volume: 40 | Issue: 1 | Pages: No page available

10.1111/ctr.70446 | PMID 41508800 Get It

ABSTRACT This study investigated the association between induction type and long‐term outcomes in kidney retransplant recipients who experienced graft loss due to BK virus–associated nephropathy (BKVAN). Using Scientific Registry of Transplant Recipients data (2003–2021), we identified 277 adult kidney‐alone retransplant recipients with BKVAN‐related graft loss and categorized them by induction regimen: depletional ( n = 217) and nondepletional ( n = 60). The groups were similar overall, except the nondepletional cohort had lower panel‐reactive antibodies, a shorter time between transplants, and more live donor kidneys. Kaplan–Meier curves assessed 10‐year recipient and graft survival, and Cox proportional hazards models, adjusted for key donor and recipient factors, evaluated associations between induction type and outcomes. Rates of delayed graft function, one‐year rejection, and estimated glomerular filtration rate were comparable between groups. Ten‐year recipient and death‐censored graft survival did not differ by induction type (recipient survival: HR 1.09; 95% CI 0.43–2.77; p = 0.85; graft survival: HR 0.85; 95% CI 0.24–2.97; p = 0.79). Recurrent BKVAN‐related graft failure occurred only in the depletional group (5 of 217; 2.3%), while rejection‐related graft failure was more common in the nondepletional group (5 of 60; 8.3% vs. 6 of 217; 2.8%). Although these differences did not translate into long‐term graft survival disparities, they highlight the competing risks of viral recurrence and rejection. Thus, clinicians should interpret these results with caution and weigh the risks and benefits of induction choice in retransplant recipients with prior BKVAN, recognizing that this observational study cannot establish causality.
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Asken, Breton M., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N., Carrillo, Maria C., Casaletto, Kaitlin B, Cash, David M, Chang, Hsin‐I., Chao, Yishu , Chételat, Gael, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hanseeuw, Bernard J, Hansson, Oskar H., Harrison, Theresa, Huang, Qi, Huang, Shu‐Hua , Ishii, K, Ishii, Kenji, Jagust, William J., Katou, Rikio, Koeppe, Robert A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J, Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis, Rowe, Christopher C., Salvadó, Gemma, Schott, Jonathan M, Schwartz, Daniel, Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz , Silbert, Lisa C, Smith, Ruben, Sokolowski, Andrzej, Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, D., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Vemuri, Prashanthi, Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Joie, Renaud La, Consortia, AMYPAD and LEADS, Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chia‐Hsuin , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kenji, Jagust, William J. , Koeppe, Robert A. , Kramer, Joel H. , Landau, Susan , Landeau, Brigitte , Lee, Sangwon, Lopresti, Brian J. , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , O’Bryant, Sid E. , Pappas, Ioannis , Peretti, Débora Elisa , Quenon, Lisa , Rowe, Christopher C., Salvadó, Gemma , Schott, Jonathan M. , Schwartz, Daniel L., Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villain, Nicolas , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107124 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen's kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure 1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure 1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure 2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure 2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.
Ethnic and Sex Differences of White Matter Tracts in Aging
Carhuavilca, Flavio, Lang, Merike, Goytizolo, Alicia, Garcia, Sebastian, Patrascanu, Adina, Duara, R., Barker, Warren W, Velez‐Uribe, Idaly, Smith, G.J.W., Rosselli, Monica, Vélez-Uribe, Idaly , Coombes, Stephen A. , Rosselli, Mónica

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106887 Get It

Abstract Background Research on gender and ethnic differences in white matter tracts yields mixed results. Although men show larger global corpus callosum (CC) in absolute values, women have demonstrated larger splenium and isthmus. Additionally, men have shown greater white matter and fractional anisotropy (FA) in multiple regions than women. This study investigates sex and ethnic differences in the corpus callosum and transcallosal white matter tissue microstructure of older individuals with normal cognition and memory disorders. Method 191 participants (Female n = 120; Hispanics n = 115; Non‐Hispanics n = 76; Age mean = 71.07; SD = 7.75) were included in the sample from the 1Florida ADRC with cognitively normal ( n = 75), MCI ( n = 88), and dementia ( n = 28) diagnoses. Corpus callosum volumes were collected using a Siemens Skyra 3T MRI scanner and were divided into anterior, mid‐anterior, central, mid‐posterior, and posterior regions. Also, MRI‐based free water diffusion tensor imaging (FW‐DTI) measured FW‐corrected FA (fwcFA) to assess and compare the integrity of transcallosal tract templates (TCATT) across motor, temporal, parietal, and occipital regions across males and females and ethnic groups. Result Univariate ANCOVAs controlling for age and clinical diagnosis were performed; females had larger normalized CC volumes in the posterior, F (1, 184) = 8.92, p = .003, η p 2 = .046, mid‐anterior, F (1,184)= 5.68, p = .018, η p 2 = .030, and anterior, F (1,184)= 14.54, p < .001, η p 2 = .073, regions, which all survived FDR corrections, with no ethnic differences observed. For transcallosal tracts, females had higher fwcFA in the inferior temporal gyrus, η p 2 Hispanics had higher fwcFA in the premotor cortex, η p 2 η p 2 Conclusion Sex and ethnicity influence white matter changes during aging independently of age and cognitive diagnosis. However, the effect explained by these demographic variables was very small, suggesting the influence of additional factors.
Sex, education and race/ethnicity have distinct effects on amyloid and tau‐PET status
Groot, Colin , Rowe, Christopher C., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Pijnenburg, Yolande A.L., Visser, Pieter Jelle, Braber, Anouk den, Pontecorvo, Michael J. , Burnham, Samantha C., Lu, Ming , Jagust, William J., Baker, Suzanne L. , Harrison, Theresa, Gispert, Juan Domingo, Shekari, Mahnaz , Minguillón, Carolina, Smith, Ruben, Mattsson‐Carlgren, Niklas, Palmqvist, Sebastian, Strandberg, Olof, Stomrud, Erik, Brickman, Adam, Manly, Jennifer J., Lao, Patrick J., Kreisl, William Charles, Malpetti, Maura, O'Brien, John T, Jäger, Elena, Bischof, Gérard, Drzezga, Alexander, Xie, Fang, Mao, Xiaoxie, Guan, Yihui, Frisoni, Giovanni B, Peretti, Débora Elisa , Skoog, I., Kern, Silke, Sperling, Reisa A., Johnson, Keith A., Risacher, Shannon, Saykin, Andrew J., Carrillo, Maria C., Dickerson, Brad C., Apostolova, Liana G., Rabinovici, Gil D., Barthel, H, Messerschmidt, Konstantin, Vandenberghe, Rik, Laere, Koen J. Van, Spruyt, Laure , Petersen, Ronald, Jack, Clifford R., Franzmeier, Nicolai, Brendel, Matthias, Gnörich, Johannes, Benzinger, Tammie L.S., Lagarde, Julien, Sarazin, Marie , Villeneuve, Sylvia , Poirier, Judes, Seo, Sang Won, Gu, Yuna , Kim, Jun Pyo, Mormino, Beth C., Vossler, Hillary , Rosa‐Neto, Pedro, Therriault, Joseph, Rahmouni, Nesrine, Cash, David M, Schott, Jonathan M, Hanseeuw, Bernard J, Jansen, Willemijn J. , Joie, Renaud La, Rosen, Howard J., Johnson, Sterling C., Christian, Bradley T, Betthauser, Tobey J., Landau, Susan M., O'Bryant, Sid E., Hansson, Oskar H., Ossenkoppele, Rik, Prevent‐AD, ADNI, ADNI‐DOD, A‐Study, MCSA,, O’Brien, John T. , O'Brien, John Tiernan , Groot, Colin , Coomans, Emma M. , Rowe, Christopher C., Doré, Vincent , Feizpour, Azadeh , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Pijnenburg, Yolande A.L. , Visser, Pieter Jelle , Braber, Anouk den , Burnham, Samantha C. , Kennedy, Ian Andrew , Jagust, William J. , Harrison, Theresa M. , Gispert, Juan Domingo , Shekari, Mahnaz , Minguillón, Carolina , Smith, Ruben, Mattsson, Niklas , Palmqvist, Sebastian , Strandberg, Olof, Stomrud, Erik , Brickman, Adam M. , Luchsinger, Jose Alejandro , Manly, Jennifer J. , Lao, Patrick , Malpetti, Maura , Rowe, James B. , Bischof, Gérard N. , Drzezga, Alexander E. , Xie, Fang , Guan, Yihui , Garibotto, Valentina , Frisoni, Giovanni B. , Schöll, Michael , Kern, Silke , Sperling, Reisa Anne , Johnson, Keith A. , Risacher, Shannon L. , Saykin, Andrew J. , Carrillo, María C. , Dickerson, Bradford Clark , Apostolova, Liana G. , Rabinovici, Gil D. , Rullmann, Michael , Messerschmidt, Konstantin, Vandenberghe, Rik , Petersen, Ronald, Jack, Clifford R. , Franzmeier, Nicolai , Brendel, Matthias , Gnörich, Johannes , Benzinger, Tammie L.S. , Lagarde, Julien , Bottlaender, Michel , Poirier, Judes , Seo, Sang Won , Kim, Jun Pyo, Young, Christina B. , Rosa-Neto, Pedro , Therriault, Joseph , Rahmouni, Nesrine , Coath, William , Cash, David M. , Schott, Jonathan M. , Hanseeuw, Bernard , Salman, Yasmine , Malotaux, Vincent , Joie, Renaud La , Rosen, Howard J. , Johnson, Sterling C. , Christian, Bradley T. , Betthauser, Tobey J. , Landau, Susan , O’Bryant, Sid E. , Hansson, Oskar , Ossenkoppele, Rik

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105387 Get It

Abstract Background Sex, education and race/ethnicity are all associated with risk of Alzheimer's disease dementia. Here, we assess the effects of self‐reported sex, educational attainment and race/ethnicity on amyloid‐positivity, and tau‐PET‐positivity in 12,048 (7,394 cognitively unimpaired [CU], 2,177 MCI, and 2,477 dementia) individuals from 42 cohorts worldwide. Method Logistic generalized estimating equations were used to estimate frequency of amyloid‐positivity (using cohort‐specific thresholds for amyloid‐PET [84%] or CSF) and tau‐PET‐positivity (cohort‐specific thresholds of 2SD above mean temporal uptake in amyloid‐negative controls). We assessed: i) sex and APOEε4 ( N = 10,098) associations, to complement earlier findings of a higher frequency of tau‐positivity in females, ii) effects of lower/higher education ( N = 10,970; cohort‐specific median‐split), and iii) effects of race/ethnicity (non‐Hispanic White [hereafter: White], N = 4880; Asian, N = 116; Black or African‐American [hereafter: Black], N = 353; Hispanic, N = 356, only from Northern‐American cohorts). Outcomes were frequency of amyloid‐positivity in CU individuals only, and tau‐PET‐positivity in both amyloid‐positive (AB+) CU and cognitively impaired (CI, i.e. MCI and dementia) individuals. Interaction effects on the relationship between age and amyloid/tau‐positivity were assessed and only retained in the models when significant. Result Female sex was associated with an APOEε4 ‐independent increased frequency of amyloid‐positivity (β=0.51[0.22], p = 0.02) in CU and increase of tau‐positivity in both AB+CU (β=0.27[0.08]) and AB+CI (β=0.37[0.08], both p <0.01). Remarkably, tau‐positivity frequencies of female APOEε4 non‐carriers were equivalent to male APOEε4 carriers in AB+CI (Figure 1). No significant sex* APOE interactions were observed. In CU, higher education was associated with lower amyloid‐positivity frequency (β=‐0.12[0.05], p = 0.02). In contrast, among AB+CU, there was an age*education interaction effect that indicated more pronounced age effects on tau‐positivity in individuals with higher education (age*education:β interaction =0.03[0.01], p <0.01). There were no education effects in AB+CI (Figure 2). In CU, an age*race/ethnicity interaction effect was observed across all non‐White groups compared to White (Hispanic:β interaction =‐0.05[0.01], p <0.01; Black:‐0.04[0.01], p <0.01; Asian:‐0.02[0.01], p = 0.04). This suggests that the impact of age on amyloid‐positivity was less pronounced in non‐White groups. Furthermore, in AB+CI, Hispanic ethnicity was related to higher tau‐positivity frequency than White (β=0.51[0.22], p = 0.02; Figure 3). Conclusion In this multi‐center initiative comprised of clinical and community‐based cohorts, we observed that self‐reported sex, educational attainment and race/ethnicity were related to positivity‐frequencies of Alzheimer's disease pathology.
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Leuzy, Antoine , Raket, Lars Lau, Villemagne, Victor L., Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Sanabria, Sandra , Boada, Mercè, Charil, A., Collins, Emily C., Collins, Jessica, Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Insel, Philip S., Irizarry, Michael C., Jack, Clifford R., Jagust, William J., Johnson, Keith A., Johnson, Sterling C., Karten, Yashmin, Marquié, Marta, Mathotaarachchi, Sulantha , Mintun, Mark A., Huang, Qi, Mao, Xiaxie, Gnörich, Johannes , Pappas, Ioannis, Petersen, Ronald, Chiotis, Konstantinos, Rabinovici, Gil D., Rosa‐Neto, Pedro, Schwarz, Christopher G, Smith, Ruben, Stephens, Andrew W., Whittington, Alex , Carrillo, M., Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Stephenson, Diane , Tatton, Nadine , Brendel, Matthias, Xie, Fang, Hansson, Oskar H., Rial, Alexis Moscoso , Rakêt, Lars Lau , Villemagne, Victor L. , Tonietto, Mattéo , Olafson, Emily, Lutz, Olivia , Boada, Merce , Betthauser, Tobey J. , Collins, Emily C. , Collins, Jessica, Gunn, Roger N. , Higuchi, Makoto, Hutchison, R. Matthew , Iaccarino, Leonardo , Insel, Philip S. , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Johnson, Keith A. , Johnson, Sterling C. , Marquié, Marta , Ossenkoppele, Rik , Pappas, Ioannis , Petersen, Ronald C. , Chiotis, Konstantinos , Rabinovici, Gil D. , Rosa-Neto, Pedro , Schwarz, Christopher G. , Smith, Ruben, Stephens, Andrew W., Carrillo, María C. , Kolb, Hartmuth C. , Brendel, Matthias , Xie, Fang , Rowe, Christopher Cleon , Hansson, Oskar , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106362 Get It

Abstract Background The Joint Propagation Model (JPM)‐based CenTauR scale was recently introduced to harmonize tau‐PET quantification across different radiotracers. This study examined how CenTauR harmonization enhances the comparability of tau‐PET quantification across matched cohorts using different tracers. The evaluation focused on three key aspects: (1) comparing tau‐PET positivity rates as defined by CenTauR, (2) evaluating its diagnostic accuracy for symptomatic AD, and (3) analyzing longitudinal changes in tau‐PET rates over time. Method The JPM, developed by the CPAD‐led Tau PET Harmonization Working Group (Leuzy et al., Alzheimers Dement. 2024; Figure 1A), models relationships between anchor point subjects and head‐to‐head tau‐PET SUVR data onto the CenTauR scale, providing conversion equations for multiple tracers. JPM equations were applied to [ 18 F]flortaucipir SUVR (Meta‐temporal ROI) data from 561 cognitively impaired participants in the ADNI and OASIS‐3 studies. Using ROC analysis, we determined the CenTauR cut‐off for positivity (T+) that maximized the Youden index for discriminating between FDA‐approved positive/negative visual reads. Three separate cohorts, scanned using [ 18 F]flortaucipir (ADNI), [ 18 F]MK‐6240 (CPAS), and [ 18 F]RO‐948 (BioFINDER‐2), were matched 1:1 by age, MMSE, amyloid‐β, and clinical diagnosis. CenTauR‐based metrics were compared across these cohorts. Result A cut‐off of 18 CenTauRs was found to optimally classify [ 18 F]flortaucipir PET visual reads (Figure 1B). The matching procedure identified 1089 participants (363 per cohort). The frequency of T+ using the 18 CenTauRs cut‐off for the Meta‐Temporal ROI was highly comparable across tracers across groups, except for the Aβ‐positive cognitively unimpaired group, where variability was more pronounced due to a smaller sample size (Figure 2A). Similarly, tau‐PET discriminative accuracy for symptomatic AD vs controls remained similar across [ 18 F]flortaucipir and [ 18 F]MK‐6240 (Figure 2B). In a separate sample of 212 matched participants from ADNI ([ 18 F]flortaucipir) and AIBL ([ 18 F]MK‐6240) with baseline and 1‐year follow‐up tau‐PET scans, 1‐year change in CenTauRs was comparable (Figure 2C). An exploratory voxelwise transformation, utilizing the Meta‐Temporal conversion equation in a representative case scanned with both [ 18 F]flortaucipir and [ 18 F]MK‐6240, demonstrates the potential for voxelwise CenTauR harmonization (Figure 3). Conclusion These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. Additional validation analyses with larger cohorts including other radiotracers ([ 18 F]PI‐2620) are underway.
Heterogeneous tau patterns in atypical AD are explained by connectivity‐associated tau progression
Bruin, Hannah de , Groot, Colin , (ADNI), Alzheimer's Disease Neuroimaging Initiative, Barthel, Henryk, Bischof, Gérard N. , Boon, Baayla D.C., Brendel, Matthias, Cash, David M, Day, Gregory S, Dickerson, Brad C., Dyck, Christopher H van, Flier, Wiesje M. van der, Fredericks, Carolyn , Fryer, Tim D. , Giessen, Elsmarieke van de, Gordon, Brian A., Radford, Jonathan Graff, Hansson, Oskar H., Höglinger, Günter U, Hönig, Merle C., Irwin, David J., Jones, P Simon, Josephs, Keith A., Katsumi, Yuta , Lee, Eddie B., Xiong, Chengjie , McGinnis, Scott M., Mecca, Adam P. , O'Brien, John T, O'Dell, Ryan S, Rabinovici, Gil D., Rahmouni, Nesrine, Rosa‐Neto, Pedro, Sabri, Osama, Schott, Jonathan M, Schroeter, Matthias L, Seeley, William W., Servaes, Stijn, Sintini, Irene , Smith, Ruben, Stevenson, Jenna , Strandberg, Olof, Therriault, Joseph, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip SJ., Whitwell, Jennifer L., Yong, Keir X X, O’Brien, John T. , Rabinovici, Gil D. , Day, Gregory S. , O'Brien, John Tiernan , Day, Gregory S , Xiong, Chengjie , Rabinovici, Gil D , Groot, Colin , Initiative, Alzheimer's Disease Neuroimaging, Blazhenets, Ganna , Boellaard, Ronald , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Dickerson, Brad C., Doering, Elena , Drzezga, Alexander E. , Dyck, Christopher H. van , Eimeren, Thilo van , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Hobbs, Diana A. , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Josephs, Keith A. , Joie, Renaud La , Lee, Eddie B, Malpetti, Maura , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Palleis, Carla , Perneczky, Robert , Phillips, Jeffrey S , Putcha, Deepti , Rahmouni, Nesrine , Rosa-Neto, Pedro , Rowe, James B. , Rullmann, Michael , Saur, Dorothee , Schildan, Andreas , Schott, Jonathan M. , Schroeter, Matthias L , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Stomrud, Erik , Therriault, Joseph , Visser, Denise , Weston, Philip S.J. , Whitwell, Jennifer L. , Wolk, David A. , Yong, Keir , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Alzheimer's & Dementia | January 7, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_104871 Get It

Abstract Background The link between regional tau load and clinical manifestation of Alzheimer's disease (AD) highlights the importance of characterizing spatial tau distribution. In typical (memory‐predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicenters. However, atypical (non‐amnestic‐predominant) AD variants with heterogeneous tau patterns provide a key opportunity to assess the universality of connectivity as a scaffold for tau progression. Method We included tau‐PET data from 320 subjects with atypical AD, characterized by highly heterogeneous tau patterns ( n = 139 posterior cortical atrophy/PCA‐AD; n = 103 logopenic variant primary progressive aphasia/lvPPA‐AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS‐AD) from 14 sites, with a subset of patients ( n = 78) having longitudinal tau‐PET data. As an independent sample, we further included regional post‐mortem tau stainings from 93 atypical AD patients from two sites ( n = 19 PCA‐AD, n = 32 lvPPA‐AD, n = 23 bvAD, n = 19 CBS‐AD). Gaussian mixture modeling was used to harmonize different tau‐PET tracers by transforming tau‐PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether 1) brain regions with stronger functional connectivity showed greater covariance in cross‐sectional and longitudinal tau‐PET and post‐mortem tau pathology, and 2) functional connectivity of tau‐PET epicenters and tau‐PET accumulation epicenters was associated with cross‐sectional and longitudinal tau patterns. Result Tau‐PET epicenters—defined as the 5% brain regions with the highest tau load—aligned with clinical variants, e.g. a posterior pattern in PCA‐AD (“visual AD”) and left‐hemispheric temporal predominance in lvPPA‐AD (“language AD”) (Figure 1). More strongly functionally connected regions showed correlated concurrent tau‐PET levels, which was confirmed with post‐mortem data (Figure 2). Moreover, the connectivity profile of tau‐PET epicenters and accumulation epicenters corresponded to tau‐PET progression patterns (Figure 3). Conclusion Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicenters, across all AD clinical variants. Since tau proteinopathy is a key driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant‐specific endpoints in clinical trials.
Exercise recommendations for older adults living with and beyond cancer: A consensus statement by the Advancing Capacity to Integrate Exercise Into the Care of Older Cancer Survivors expert panel
Winters‐Stone, Kerri M. , Meyers, G., Cheville, Andrea , Garcia, José M. , Mohile, Supriya G. , Mustian, Karen, Neil‐Sztramko, Sarah, Schwartz, Anna L. , Sitemba, Jessica, Smith, Robert, Campbell, K., Mustian, Karen M. , Neil‐Sztramko, Sarah , Cheville, Andrea L , McNeely, Margaret L , Neil-Sztramko, Sarah , Schmitz, Kathryn H , Campbell, Kristin L , Winters-Stone, Kerri M , Garcia, Jose M , Eckstrom, Elizabeth , Rogers, Laura Q. , Schmitz, Kathryn H.

Mayo Clinic

Cancer | January 7, 2026 | Volume: 132 | Issue: 2 | Pages: No page available

10.1002/cncr.70252 | PMID 41499155 Get It

Abstract Background The number of cancer survivors aged older than 65 years is rising rapidly. Current evidence‐based exercise guidelines lack specific guidance for older cancer survivors as a result of insufficient evidence. An expert panel was convened to develop consensus‐based recommendations for exercise in older cancer survivors. Methods The development of recommendations was guided by the Grading of Recommendations Assessment, Development, and Evaluation Evidence‐to‐Decision framework for good practice statements. The panel drew from the available literature, a Delphi survey of exercise and health professionals, other exercise guidelines, clinical and research expertise, and interest‐holder input provided by a community advisory board of older cancer survivors and caregivers ( n = 11). Recommendations had to be deemed accessible (i.e., no added barriers) to older cancer survivors and feasible to implement. The panel voted on the strength of the recommendation for or against each statement, with consensus set at 85% agreement. Results Consensus was reached on 11 recommendations covering the following areas: medical evaluation/clearance for exercise, pre‐exercise assessment, exercise prescription, exercise tolerance and safety, exercise delivery, and behavioral support. The recommendations aimed to promote engagement in and uptake of appropriately prescribed exercise programming by older cancer survivors, while keeping barriers and risks as low as possible. Conclusions Older cancer survivors can benefit from appropriately prescribed exercise, which should be an essential component of their cancer care. Exercise and health professionals need to consider the unique needs of older cancer survivors to ensure that exercise is safe and effective for this population, while also reducing barriers to reach as many people as possible.
Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study
McNamara, Dennis M. , Cooper, Leslie, Arbel, Yaron, Bocchi, Edimar, Hamer, A. J. , Herdy, Artur Haddad , Kerneis, Mathieu, Liu, Peter P., Parker, Andrea B., Pocock, Stuart , Smith, Eldon R., Tang, W H Wilson, Torre-Amione, Guillermo, Tschöpe, Carsten , Group, ARCHER Study, Bocch, Edimar, Moreira, Maria da Consolação Vieira , Dytz, Eduardo, Neuenschwander, Fernando Carvalho , Silva, Luís Beck da, Pezel, Theo, Abtan, Jeremie, Puymirat, Étienne , Moravsky, Gil, Piltz, Xavier Alejandro, Orlev, Amir , Bhat, Pavan , Thomas, Georgia , Lin, David, Palmer, Brittany, Kerneis, Mathieu , Pocock, Stuart J , McNamara, Dennis M , Tschöpe, Carsten , Friedrich, Matthias G. , Arbel, Yaron , Bhimaraj, Arvind , Hamer, Andrew, Tang, W.H. Wilson , Torre‐Amione, Guillermo , Caramori, Paulo , Moura, Lídia Zytynski , Macedo, Ariane Vieira Scarlatelli , Albuquerque, Denílson Campos de , Beck-da-Silva, Luís , Lattuca, Benoît , Bouleti, Claire , Pezel, Théo , Abtan, Jérémie , Delmas, Clément , Huang, Florent , Roubille, François , Bochaton, Thomas , Piltz, Xavier, Zlotoff, Daniel A , Hofmeyer, Mark R. , Hamer, Andrew

Mayo Clinic

ESC Heart Failure | January 6, 2026 | Volume: 13 | Issue: 1 | Pages: No page available

10.1093/eschf/xvaf034 | PMID 41711722 Get It

Abstract Introduction Cannabidiol has been shown to exert significant anti-inflammatory effects and has demonstrated efficacy in murine models of autoimmune myocarditis, pericarditis, and heart failure. The ARCHER Study assessed whether a pharmaceutically produced cannabidiol formulation showed beneficial effects on cardiac magnetic resonance (CMR) endpoints known to predict prognosis in this patient population. Methods In a multicentre international double-blind placebo-controlled phase 2 study, we randomly assigned 109 patients within 10 days of CMR confirmed diagnosis of acute myocarditis to 12 weeks of pharmaceutically produced oral cannabidiol (active) or placebo. Dose was titrated up to 10 mg/kg of body weight twice daily. Primary endpoints were the difference in extracellular volume (ECV) and global longitudinal strain (GLS) measured by CMR at week 12. Other CMR endpoints included left-ventricular ejection fraction (LVEF), LV mass, intracellular volume (ICV), LV end-diastolic and end-systolic volumes (LVEDV, LVESV), and left-atrial end-systolic volume (LAESV). Results All randomized patients (56 active/53 placebo) completed the study with no loss to follow-up. Study drug appeared safe and well tolerated. Baseline mean ECV 38.9 ± 10.9 ml, GLS −15.3 ± 3.6%, and LVEF 60.6 ± 9.9% were consistent with mild to moderate myocarditis and predominantly intact LV function. Week 12 mean ECV was 33.6 ml in the active group and 37.3 ml in the placebo group, a difference of −3.7 ml, confidence interval (CI): −7.4 to 0.1; P = .0538; GLS was −16.0% in the active group and −15.9% in the placebo group, difference of −0.1, CI: −1.2 to 1.1; P = .90. Left ventricular mass was significantly reduced in the active group at 121.1 g compared to placebo 130.3 g, a difference of −9.2, CI: −16.4 to −2.1; P = .0117. In terms of remodelling, LAESV was significantly reduced in the active group (−8.1 ml; P = .0376) while the reduction in LVEDV failed to reach significance (−7.4 ml; P = .098). Conclusion In mild-to-moderate acute myocarditis, treatment with pharmaceutically manufactured cannabidiol was not associated with a statistically significant change in myocardial ECV or GLS, although a trend towards reduction in ECV was observed. In addition, improvement in other potential markers of myocardial recovery, including a significant reduction in LV mass, was seen in the active treatment group. Further investigation of the therapeutic potential of this therapy in inflammatory cardiac conditions is warranted.